U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT06952634) titled 'An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage' on April 22.
Brief Summary: This a phase 1, open label, single dose, parallel cohort study to determine the pharmacokinetics (PK) of study drug (ESK-001) in healthy volunteer participants, and participants with mild, moderate, and severe hepatic impairment.
Study Start Date: April 29
Study Type: INTERVENTIONAL
Condition:
Hepatic Impairment
Intervention:
DRUG: ESK-001
Single oral dose of ESK-001 in participants from all cohorts
Recruitment Status: RECRUITING
Sponsor: Alumis Inc
Publishe...